Potential vascular benefits of statins

American Journal of Medicine

Volumn 118, Issue 12 SUPPL., 2005, Pages 62-67

  Kinlay, Scott ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b VA BOSTON HEALTHCARE SYSTEM   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Low density lipoprotein independent; Pleiotropic; Risk; Statins

Indexed keywords

CAVEOLIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENOID; LIPID; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE SYNTHASE;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CELL CULTURE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DRUG POTENCY; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; IMMUNOMODULATION; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RISK REDUCTION; THROMBOSIS; VASOMOTOR REFLEX;

EID: 28844506346     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2005.09.007     Document Type: Conference Paper

References (58)

1. S. Kinlay, A.P. Selwyn, D. Delagrange, M.A. Creager, P. Libby, P. Ganz Biological mechanisms for the clinical success of lipid-lowering in coronary artery disease and the use of surrogate end-points Curr Opin Lipidol 7 1996 389 397
2. D.S. Celermajer, K.E. Sorensen, C. Bull, J. Robinson, J.E. Deanfield Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction J Am Coll Cardiol 24 1994 1468 1474
3. T. Heitzer, S. Yla-Herttuala, J. Luoma Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia role of oxidized LDL Circulation 93 1996 1346 1353
4. M.T. Johnstone, S.J. Creager, K.M. Scales, J.A. Cusco, B.K. Lee, M.A. Creager Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus Circulation 88 1993 2510 2516
5. S. Taddei, A. Virdis, P. Mattei Hypertension causes premature aging of endothelial function in humans Hypertension 29 1997 736 743
6. J.A. Vita, C.B. Treasure, E.G. Nabel Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease Circulation 81 1990 491 497
7. A.M. Zeiher, H. Drexler, H. Wollschlager, H. Just Modulation of coronary vasomotor tone in humans progressive endothelial dysfunction with different early stages of coronary atherosclerosis Circulation 83 1991 391 401
8. T.J. Anderson, I.T. Meredith, A.C. Yeung, B. Frei, A.P. Selwyn, P. Ganz The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion N Engl J Med 332 1995 488 493
9. K. Egashira, Y. Hirooka, H. Kai Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia Circulation 89 1994 2519 2524
10. R. Hambrecht, A. Wolf, S. Gielen Effect of exercise on coronary endothelial function in patients with coronary artery disease N Engl J Med 342 2000 454 460
11. Y. Higashi, S. Sasaki, N. Sasaki Daily aerobic exercise improves reactive hyperemia in patients with essential hypertension Hypertension 33 1999 591 597
12. W.H. Leung, C.P. Lau, C.K. Wong Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients Lancet 341 1993 1496 1500
13. O. Tamai, H. Matsuoka, H. Itabe, Y. Wada, K. Kohno, T. Imaizumi Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans Circulation 95 1997 76 82
14. C.B. Treasure, J.L. Klein, W.S. Weintraub Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease N Engl J Med 332 1995 481 487
15. M. Aikawa, S. Sugiyama, C.C. Hill Lipid lowering reduces oxidative stress and endothelial cell activation in rabbit atheroma Circulation 106 2002 1390 1396
16. M. Crisby, G. Nordin-Fredriksson, P.K. Shah, J. Yano, J. Zhu, J. Nilsson Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques implications for plaque stabilization Circulation 103 2001 926 933
17. T.C. Andrews, K. Raby, J. Barry Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease Circulation 95 1997 324 328
18. A.J. van Boven, J.W. Jukema, A.H. Zwinderman, H.J. Crijns, K.I. Lie, A.V. Bruschke Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris Circulation 94 1996 1503 1505
19. P. Libby Molecular bases of the acute coronary syndromes Circulation 91 1995 2844 2850
20. P. Libby Current concepts of the pathogenesis of the acute coronary syndromes Circulation 104 2001 365 372
21. R. De Caterina, P. Libby, H.B. Peng Nitric oxide decreases cytokine-induced endothelial activation nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines J Clin Invest 96 1995 60 68
22. M. Aikawa, E. Rabkin, Y. Okada Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma a potential mechanism of lesion stabilization Circulation 97 1998 2433 2444
23. M. Aikawa, E. Rabkin, S. Sugiyama An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro Circulation 103 2001 276 283
24. C. Bustos, M.A. Hernandez-Presa, M. Ortego HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis J Am Coll Cardiol 32 1998 2057 2064
25. S. Jern, U. Wall, A. Bergbrant, L. Selin-Sjogren, C. Jern Endothelium-dependent vasodilation and tissue-type plasminogen activator release in borderline hypertension Arterioscler Thromb Vasc Biol 17 1997 3376 3383
26. D.E. Newby, R.A. Wright, P. Dawson The l-arginine/nitric oxide pathway contributes to the acute release of tissue plasminogen activator in vivo in man Cardiovasc Res 38 1998 485 492
27. N.P. Andrews, M. Husain, N. Dakak, A.A. Quyyumi Platelet inhibitory effect of nitric oxide in the human coronary circulation impact of endothelial dysfunction J Am Coll Cardiol 37 2001 510 516
28. J.G. Diodati, N. Dakak, D.M. Gilligan, A.A. Quyyumi Effect of atherosclerosis on endothelium-dependent inhibition of platelet activation in humans Circulation 98 1998 17 24
29. A. Schafer, F. Wiesmann, S. Neubauer, M. Eigenthaler, J. Bauersachs, K.M. Channon Rapid regulation of platelet activation in vivo by nitric oxide Circulation 109 2004 1819 1822
30. T. Bourcier, P. Libby HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells Arterioscler Thromb Vasc Biol 20 2000 556 562
31. S. Lopez, F. Peiretti, B. Bonardo, I. Juhan-Vague, G. Nalbone Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells Atherosclerosis 152 2000 359 366
32. F. Wiesbauer, C. Kaun, G. Zorn, G. Maurer, K. Huber, J. Wotja HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro a comparative study using different statins Br J Pharmacol 135 2002 284 292
33. S. Kinlay, G.G. Schwartz, A.G. Olsson Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Circulation 110 2004 386 391
34. U. Schonbeck, N. Gerdes, N. Varo Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells Circulation 106 2002 2888 2893
35. A.G. Semb, S. van Wissen, T. Ueland Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia downregulatory effect of statin therapy J Am Coll Cardiol 41 2003 275 279
36. S. Kinlay, P. Libby, P. Ganz Endothelial function and coronary artery disease Curr Opin Lipidol 12 2001 383 389
37. D.J. Gordon, J.L. Probstfield, R.J. Garrison High-density lipoprotein cholesterol and cardiovascular disease four prospective American studies Circulation 79 1989 8 15
38. J. Pekkanen, S. Linn, G. Heiss Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease N Engl J Med 322 1990 1700 1707
39. A.G. Shaper, S.J. Pocock, M. Walker, A.N. Phillips, T.P. Whitehead, P.W. Macfarlane Risk factors for ischaemic heart disease the prospective phase of the British Regional Heart Study J Epidemiol Community Health 39 1985 197 209
40. H.B. Brewer Jr Increasing HDL cholesterol levels N Engl J Med 350 2004 1491 1494
41. L.E. Spieker, I. Sudano, D. Hurlimann High-density lipoprotein restores endothelial function in hypercholesterolemic men Circulation 105 2002 1399 1402
42. A. Ceriello, C. Taboga, L. Tonutti Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation effects of short- and long-term simvastatin treatment Circulation 106 2002 1211 1218
43. S.E. Nissen, E.M. Tuzcu, P. Schoenhagen REVERSAL Investigators Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis a randomized controlled trial JAMA 291 2004 1071 1080
44. T.J. Smilde, S. van Wissen, H. Wollersheim, M.D. Trip, J.J. Kastelein, A.F. Stalenhoef Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP) a prospective, randomised, double-blind trial Lancet 357 2001 577 581
45. A.J. Taylor, S.M. Kent, P.J. Flaherty, L.C. Coyle, T.T. Markwood, M.N. Vernalis ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness Circulation 106 2002 2055 2060
46. U. Laufs, J.K. Liao Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by rho GTPase J Biol Chem 273 1998 24266 24271
47. O. Feron, L. Belhassen, L. Kobzik, T.W. Smith, R.A. Kelly, T. Michel Endothelial nitric oxide synthase targeting to caveolae specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells J Biol Chem 271 1996 22810 22814
48. T. Michel, O. Feron Nitric oxide synthases which, where, how, and why? J Clin Invest 100 1997 2146 2152
49. O. Feron, C. Dessy, S. Moniotte, J.P. Desager, J.L. Balligand Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase J Clin Invest 103 1999 897 905
50. O. Feron, C. Dessy, J.P. Desager, J.L. Balligand Hydroxy-methylglutaryl- coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance Circulation 103 2001 113 118
51. A. Brouet, P. Sonveaux, C. Dessy, S. Moniotte, J.L. Balligand, O. Feron Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins Circ Res 89 2001 866 873
52. B. Kwak, F. Mulhaupt, S. Myit, F. Mach Statins as a newly recognized type of immunomodulator Nat Med 6 2000 1399 1402
53. P.S. Frenette Locking a leukocyte integrin with statins N Engl J Med 345 2001 1419 1421
54. I.S. Ockene, C.E. Matthews, N. Rifai, P.M. Ridker, G. Reed, E. Stanek Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults Clin Chem 47 2001 444 450
55. S. Kinlay, A.P. Selwyn Effects of statins on inflammation in patients with acute and chronic coronary syndromes Am J Cardiol 91 2003 9B 13B
56. P.M. Ridker, M. Cushman, M.J. Stampfer, R.P. Tracy, C.H. Hennekens Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men N Engl J Med 336 1997 973 979
57. C.P. Cannon, E. Braunwald, C.H. McCabe Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
58. S. Kinlay, G.G. Schwartz, A.G. Olsson Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study Investigators High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study Circulation 108 2003 1560 1566